NanoViricides Highlights NV-387's Potential Against COVID-19

SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC), a clinical stage leader in antiviral nanomedicines, highlights the strong safety and effectiveness of its lead drug candidate NV-387 against coronaviruses.

President Joe Biden’s recovery from a new COVID variant underscores the need for potent drugs, a gap NV-387 aims to address. COVID remains a significant health challenge in the U.S., with biannual waves of new variants causing higher fatalities and hospitalizations than Influenza.

In animal studies, NV-387 significantly improved survival rates compared to Remdesivir (Veklury®, Gilead). IV administration of NV-387 in infected rats showed a 180% survival increase, versus Remdesivir's 50%. Oral NV-387 also demonstrated high effectiveness with an 88% increase.

Despite the focus on vaccines and antibodies, limitations have emerged. Currently, Paxlovid™ (Pfizer) is the only available oral COVID drug, though its clinical effectiveness is questionable. NV-387's broad antiviral spectrum and safety indicate it may fill a crucial public health need.

NanoViricides is pursuing collaborations to advance NV-387 towards regulatory approval for multiple antiviral uses. Phase I trials in India showed excellent safety and tolerability for NV-387 in oral formulations, without adverse events at high dosages.